Cystic Fibrosis Clinical Trial
— ISICOfficial title:
Comparison of Showerpatch Versus Other Measures to Protect Intravenous Catheter Entry Site During Bathing Activities
Venous catheters are necessary for the treatment of many patients. Showering with a venous catheter is often prohibited due to the infection risk when the insertion site becomes wet. Therefore these patients are challenged to keep the catheter insertion site dry and always covered with a dressing. Washing themselves is often impossible without assistance of a nurse or significant other. For patients with a catheter connected to an infusion line, it is even more difficult. Showerpatch is a newly developed dressing that safeguards the insertion site of an IV catheter from water during bathing activities. The purpose of this trial is to evaluate the impact of the availability of Showerpatch by comparing the outcomes in patients regarding the patient's autonomy in bathing activities, the material use and the time needed from caregivers in home care. Additionally qualitative data on patient's bathing activities and the use of Showerpatch will be collected.
Status | Terminated |
Enrollment | 18 |
Est. completion date | March 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - able to read and speak Dutch and to fill out a web-based questionnaire - patients with an IV catheter (peripheral catheter, midline, peripherally inserted central catheter (PICC), Central Venous catheter (CVC), tunnelled catheter or implantable port) with an expected dwell time IV therapy of at least 14 days and with or without a prospect of discharge to the home setting with the IV catheter in situ in the foreseen study period - physically able to wash themselves - with access to the internet Exclusion Criteria: - Bedridden patients - Patients who have already participated in an earlier stage of the ISIC study - Patients with more than one lumen of the catheter continuously connected to an infusion line |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Belgium | University Hospitals Leuven | Leuven |
Lead Sponsor | Collaborator |
---|---|
Universitaire Ziekenhuizen Leuven | BEDAL, Remedus |
Belgium,
Do AN, Ray BJ, Banerjee SN, Illian AF, Barnett BJ, Pham MH, Hendricks KA, Jarvis WR. Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. J Infect Dis. 1999 Feb;179(2):442-8. — View Citation
Molloy D, Smith LN, Aitchison T. Cytotoxic chemotherapy for incurable colorectal cancer: living with a PICC-line. J Clin Nurs. 2008 Sep;17(18):2398-407. doi: 10.1111/j.1365-2702.2008.02359.x. — View Citation
O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S; Healthcare Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011 May;39(4 Suppl 1):S1-34. doi: 10.1016/j.ajic.2011.01.003. — View Citation
Oakley C, Wright E, Ream E. The experiences of patients and nurses with a nurse-led peripherally inserted central venous catheter line service. Eur J Oncol Nurs. 2000 Dec;4(4):207-18. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Skin irritation after application of Showerpatch | Redness or other sign of skin irritation at the place where adhesive of the new protection dressing had contact with the skin on a yes/no basis | Before and after bathing activities, reported until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | Yes |
Other | Catheter/Huber needle status | Expressed on a 3-point scale from 0 which means correct in place to 2 totally removed | Before and after bathing activities, reported until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | Yes |
Primary | Self-reported autonomy score regarding bathing activities | autonomy regarding bathing activities will be scored on a newly developed autonomy scale on a weekly basis | Weekly until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | No |
Secondary | Number and type of bathing activities | Number and type of bathing activities per week | Weekly reported, until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | No |
Secondary | Catheter dressing status: wet | Expressed on a 3-point scale from 0 which means not wet to 2 totally wet | Before and after bathing activities, reported until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | Yes |
Secondary | Catheter dressing status: loose | Expressed on a 3-point scale from 0 which means not loose to 2 totally loose | Before and after bathing activities, reported until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | Yes |
Secondary | Time needed from a caregiver | Time expressed in minutes per week | Weekly reported, until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | No |
Secondary | Material consumption regarding IV entry site care for bathing activities | Description of material which was used for catheter dressing protection and/or for the extra dressing change and/or extra securement of the dressing afterwards. | Weekly reported, until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | No |
Secondary | Clinical signs of local infection | Redness, tenderness, warmth, swelling or pus leakage recorded on a yes/no basis | Before and after bathing activities, reported until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | Yes |
Secondary | Laboratory-Confirmed Bloodstream Infection | Collected at the end of the study by retrospective analysis of the patient file in case of hospital admission | Until catheter removal which is expected on an average after 2 weeks or up to 8 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |